Dashboard
Manage Tickers

CABA


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target
Cantor Fitzgerald Reiterates Overweight on...
04/05/2024 13:19:03

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

citigroup-maintains-buy-on-cabaletta-bio-raises-price-target-to-30
Citigroup Maintains Buy on Cabaletta Bio, ...
04/04/2024 15:47:06

Citigroup analyst Samantha Semenkow maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target from $26 to...

cabaletta-bio-issued-idnct06328777-for-phase-12-open-label-study-to-evaluate-the-safety-and-efficacy-of-caba-201-a-cd19-car-t-cell-therapy-in-subjects-with-systemic-sclerosis-posted-to-clinical-trials-website-on-2024-03-25-study-is-not-yet-recruiting
Cabaletta Bio Issued ID#NCT06328777 For Ph...
03/25/2024 14:25:25

https://clinicaltrials.gov/study/NCT06328777   Inclusion Criteria:

cantor-fitzgerald-reiterates-overweight-on-cabaletta-bio-maintains-50-price-target
Cantor Fitzgerald Reiterates Overweight on...
03/22/2024 17:54:33

Cantor Fitzgerald analyst Joshua Schimmer reiterates Cabaletta Bio (NASDAQ:CABA) with a Overweight and maintains $50 price t...

wells-fargo-maintains-overweight-on-cabaletta-bio-raises-price-target-to-35
Wells Fargo Maintains Overweight on Cabale...
03/22/2024 17:40:24

Wells Fargo analyst Derek Archila maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and raises the price target from $...

hc-wainwright--co-maintains-buy-on-cabaletta-bio-raises-price-target-to-30
HC Wainwright & Co. Maintains Buy on Cabal...
03/22/2024 14:55:45

HC Wainwright & Co. analyst Douglas Tsao maintains Cabaletta Bio (NASDAQ:CABA) with a Buy and raises the price target fr...

recap-cabaletta-bio-q4-earnings
Recap: Cabaletta Bio Q4 Earnings
03/21/2024 13:10:06

cabaletta-bio-inc-files-for-mixed-shelf-offering-size-not-disclosed
Cabaletta Bio Inc Files For Mixed Shelf Of...
03/21/2024 12:05:33

- SEC Filing

cabaletta-bio-q4-eps-046-misses-039-estimate-cabaletta-had-cash-cash-equivalents-and-short-term-investments-of-2412m-expected-to-fund-its-operating-plan-into-the-first-half-of-2026
Cabaletta Bio Q4 EPS $(0.46) Misses $(0.39...
03/21/2024 11:22:50

Cabaletta Bio (NASDAQ:CABA) reported quarterly losses of $(0.46) per share which missed the analyst consensus estimate of $(0.3...

fda-granted-orphan-drug-designation-to-cabaletta-bios-caba-201-for-treatment-of-systemic-sclerosis
FDA Granted Orphan Drug Designation To Cab...
03/20/2024 11:03:04

cramer-this-reit-is-a-little-too-dicey-as-for-marathon-digital-own-the-pure
Cramer: This REIT Is 'A Little Too Dicey';...
03/06/2024 14:20:57

On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended holding onto Regions Financial Corporation (NYSE: RF).

jefferies-initiates-coverage-on-cabaletta-bio-with-buy-rating-announces-price-target-of-36
Jefferies Initiates Coverage On Cabaletta ...
02/05/2024 11:00:06

Jefferies analyst Kelly Shi initiates coverage on Cabaletta Bio (NASDAQ:CABA) with a Buy rating and announces Price Target o...

cabaletta-bio-announces-fda-granted-orphan-drug-designation-to-caba-201-for-treatment-of-myositis
Cabaletta Bio Announces FDA Granted Orphan...
02/01/2024 21:40:43

12-health-care-stocks-moving-in-mondays-after-market-session
12 Health Care Stocks Moving In Monday's A...
01/22/2024 21:31:12

cabaletta-bio-gets-additional-fda-fast-track-designations-for-caba-201-in-dermatomyositis-and-systemic-sclerosis
Cabaletta Bio Gets Additional FDA Fast Tra...
01/08/2024 12:05:40

To date, Cabaletta has received clearance from the FDA for Investigational New Drug (IND) applications for CABA-201 in multiple...

verint-reports-strong-earnings-joins-semtech-alphabet-and-other-big-stocks-moving-higher-on-thursday
Verint Reports Strong Earnings, Joins Semt...
12/07/2023 15:17:42

U.S. stocks traded mostly higher, with the Nasdaq Composite gaining more than 100 points on Thursday.

morgan-stanley-maintains-overweight-on-cabaletta-bio-lowers-price-target-to-25
Morgan Stanley Maintains Overweight on Cab...
11/29/2023 15:02:25

Morgan Stanley analyst Michael Ulz maintains Cabaletta Bio (NASDAQ:CABA) with a Overweight and lowers the price target from ...

analyst-ratings-for-cabaletta-bio
Analyst Ratings for Cabaletta Bio
11/29/2023 12:00:31

hc-wainwright--co-reiterates-buy-on-cabaletta-bio-maintains-25-price-target
HC Wainwright & Co. Reiterates Buy on Caba...
11/29/2023 11:14:48

HC Wainwright & Co. analyst Douglas Tsao reiterates Cabaletta Bio (NASDAQ:CABA) with a Buy and maintains $25 price target.

leslies-posts-weak-earnings-joins-las-vegas-sands-verve-therapeutics-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Leslie's Posts Weak Earnings, Joins Las Ve...
11/29/2023 10:48:40

U.S. stock futures traded higher this morning, with the Dow Jones futures gaining around 100 points on Wednesday.

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION